
The pertuzumab biosimilar is set to be commercially available in the third quarter of 2028.
Bruce A. Feinberg, DO, vice president and chief medical officer of Cardinal Health Specialty Solutions, discusses the key elements of an effective cancer clinical care pathways program.
Bruce A. Feinberg, DO, vice president and chief medical officer of Cardinal Health Specialty Solutions, discusses the key elements of an effective cancer clinical care pathways program.





